These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37866327)

  • 21. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
    Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reliability and validity of the Thai self-report version of the Yale-Brown Obsessive-Compulsive Scale-Second Edition.
    Hiranyatheb T; Saipanish R; Lotrakul M; Prasertchai R; Ketkaew W; Jullagate S; Udomsubpayakul U; Kusalaruk P
    Neuropsychiatr Dis Treat; 2015; 11():2817-24. PubMed ID: 26604766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.
    Paydary K; Akamaloo A; Ahmadipour A; Pishgar F; Emamzadehfard S; Akhondzadeh S
    J Clin Pharm Ther; 2016 Apr; 41(2):214-9. PubMed ID: 26931055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Bullock KD; Franz B; Gamel N; Elliott M
    J Clin Psychiatry; 2005 Mar; 66(3):353-9. PubMed ID: 15766302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. D-cycloserine augmentation in behavioral therapy for obsessive-compulsive disorder: a meta-analysis.
    Xia J; Du Y; Han J; Liu G; Wang X
    Drug Des Devel Ther; 2015; 9():2101-17. PubMed ID: 25960632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study.
    Li F; Welling MC; Johnson JA; Coughlin C; Mulqueen J; Jakubovski E; Coury S; Landeros-Weisenberger A; Bloch MH
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):32-37. PubMed ID: 31800306
    [No Abstract]   [Full Text] [Related]  

  • 29. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Shannahoff-Khalsa D; Fernandes RY; Pereira CAB; March JS; Leckman JF; Golshan S; Vieira MSR; Polanczyk GV; Miguel EC; Shavitt RG
    Front Psychiatry; 2019; 10():793. PubMed ID: 31780963
    [No Abstract]   [Full Text] [Related]  

  • 30. Criterion Validity of the Yale-Brown Obsessive-Compulsive Scale Second Edition for Diagnosis of Obsessive-Compulsive Disorder in Adults.
    Castro-Rodrigues P; Camacho M; Almeida S; Marinho M; Soares C; Barahona-Corrêa JB; Oliveira-Maia AJ
    Front Psychiatry; 2018; 9():431. PubMed ID: 30254588
    [No Abstract]   [Full Text] [Related]  

  • 31. The safety and efficacy of transcranial direct current stimulation as add-on therapy to fluoxetine in obsessive-compulsive disorder: a randomized, double-blind, sham-controlled, clinical trial.
    Yoosefee S; Amanat M; Salehi M; Mousavi SV; Behzadmanesh J; Safary V; Yoonesi A; Salehi B
    BMC Psychiatry; 2020 Nov; 20(1):570. PubMed ID: 33256659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
    Afshar H; Roohafza H; Mohammad-Beigi H; Haghighi M; Jahangard L; Shokouh P; Sadeghi M; Hafezian H
    J Clin Psychopharmacol; 2012 Dec; 32(6):797-803. PubMed ID: 23131885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies.
    Brown LT; Mikell CB; Youngerman BE; Zhang Y; McKhann GM; Sheth SA
    J Neurosurg; 2016 Jan; 124(1):77-89. PubMed ID: 26252455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).
    Soomro GM; Altman D; Rajagopal S; Oakley-Browne M
    Cochrane Database Syst Rev; 2008 Jan; 2008(1):CD001765. PubMed ID: 18253995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hoarding symptoms and prediction of poor response to limbic system surgery for treatment-refractory obsessive-compulsive disorder.
    Gentil AF; Lopes AC; Dougherty DD; Rück C; Mataix-Cols D; Lukacs TL; Canteras MM; Eskandar EN; Larsson KJ; Hoexter MQ; Batistuzzo MC; Greenberg BD; Miguel EC
    J Neurosurg; 2014 Jul; 121(1):123-30. PubMed ID: 24702323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.
    Rutrick D; Stein DJ; Subramanian G; Smith B; Fava M; Hasler G; Cha JH; Gasparini F; Donchev T; Ocwieja M; Johns D; Gomez-Mancilla B
    Adv Ther; 2017 Feb; 34(2):524-541. PubMed ID: 28044255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial.
    Mowla A; Boostani S; Dastgheib SA
    J Clin Psychopharmacol; 2016 Dec; 36(6):720-723. PubMed ID: 27811556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systematic Review and Meta-analysis: An Empirical Approach to Defining Treatment Response and Remission in Pediatric Obsessive-Compulsive Disorder.
    Farhat LC; Vattimo EFQ; Ramakrishnan D; Levine JLS; Johnson JA; Artukoglu BB; Landeros-Weisenberger A; Asbahr FR; Cepeda SL; Comer JS; Fatori D; Franklin ME; Freeman JB; Geller DA; Grant PJ; Goodman WK; Heyman I; Ivarsson T; Lenhard F; Lewin AB; Li F; Merlo LJ; Mohsenabadi H; Peris TS; Piacentini J; Rosa-Alcázar AI; Rosa-Alcázar À; Rozenman M; Sapyta JJ; Serlachius E; Shabani MJ; Shavitt RG; Small BJ; Skarphedinsson G; Swedo SE; Thomsen PH; Turner C; Weidle B; Miguel EC; Storch EA; Mataix-Cols D; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2022 Apr; 61(4):495-507. PubMed ID: 34597773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.